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Abstract - The effects of chronic treatments with either SRIH-14 or octreotide on the adrenal medulla of male Wistar 
rats were examined. Adult males received subcutaneous (s.c.) injections of 20 μg/100 g body weight of either SRIH-14 or 
octreotide twice a day for 28 consecutive days. The absolute weights and the absolute volumes of the adrenal glands 
significantly (p<0.05) decreased after either treatment. The adrenal medulla was analyzed by histological and 
stereological methods using newCAST. Compared to the control, the relative volumes of the vascular tissues 
significantly (p < 0.05) decreased – by 40% and 25% in the SRIH-14- and octreotide-treated groups, respectively. In the 
SRIH-14- and octreotide-treated groups the relative volumes of chromaffin and interstitial tissue increased by 6% and 
5% (p < 0.05), respectively. These findings show that both SRIH-14 and octreotide affect the morphological 
characteristics of the adrenal zona medullaris in a similar manner. 
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INTRODUCTION 
The neuropeptide somatostatin (somatostatin-
release inhibitory hormone or SRIH) is involved in 
multiple inhibitory actions throughout the central 
and peripheral nervous systems (Patel, 1999). 
SRIH is synthesized as part of a large precursor 
molecule which is enzymatically cleaved into a 
prohormone form that is further processed to 
yield two active forms, SRIH 14 and SRIH 28 
(Reichlin, 1983a, 1983b). Somatostatin acts 
through specific membrane-bound receptors (sst) 
that belong to the seven-transmembrane receptor 
super family. Five different receptor subtypes are 
recognized. Different experimental approaches 
showed that different sst receptors are expressed in 
normal and in tumor tissues (Patel, 1999). Because 
of its potent inhibitory effect on hormone 
secretion the use of SRIH in clinical disorders 
related to excessive hormone secretion has been 
proposed. Octreotide, a short synthetic somato-
statin analogue, was introduced for clinical use in 
cancer therapy and treatments of gastrointestinal 
and hormonal hypersecretory disorders 
(Weckbecker et al., 1993). It is more powerful then 
endogenous SRIH because of its longer half-life 
(Bauer et al., 1982; Lamberts et al., 1991). Octreo-
tide binds with high affinity to sst2 and sst5 
receptors, with a moderate affinity to subtype 3 
receptors, but it does not bind to either subtype 1 
or 4 receptors (Rossowski & Coy, 1994). 
The adrenal gland could also be a potential 
target for direct SRIH action. Somatostatin 
receptors have been detected in the rat adrenal 
cortex and medulla (Aguilera et al.,1982; Maurer 
and Reubi, 1986). However, in healthy male adult 
rats, intracerebroventricular (ICV) application of 
SRIH affects the morphometric features of the 
adrenal cortex and the plasma aldosterone level 
(Milošević et al., 1996). 
The aim of this study was to investigate the 
effects of chronic treatments with either SRIH-14 or 
octreotide on the stereological parameters of the 
adrenal zona medullaris using newCAST. 
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MATERIALS AND METHODS 
All experimental protocols were approved by the 
Local Animal Care Committee. They conformed to the 
recommendations provided in the Guide for the Care 
and Use of Laboratory Animals (1996, National 
Academy Press, Washington D.C.). Adult Wistar males 
rats were divided into three experimental groups, two 
treated and one control. Rats in the first and second 
groups were injected s.c. twice a day with 20 μg/100g b. 
w. of either SRIH-14 or octreotide for 28 consecutive 
days. There were six animals in each group. The 
animals were decapitated 24 h after the last injection. 
Adrenal glands were excised, fixed in Bouin’s solution 
for 48 h, dehydrated and embedded in paraffin. The 
adrenal medulla was analyzed by histological and 
stereological methods using newCAST. Every tenth 
section (5 μm thick), was used for stereological analysis; 
the first section was randomly chosen. The zona 
medullaris was circumscribed and a point grid was used 
to estimate the relative percent changes in the volumes 
of chromaffin and interstitial tissues, and the volume of 
the vascular tissue. Two individual point grid systems 
were chosen: one for the chromaffin and interstitial 
tissues and one for the vascular tissue. About 200 
matches per animal were assumed. The areas of both 
grids were identical, and the point areas were not. The 
volumes were estimated according to Cavalieri (1966). 
The volumes of chomaffin cells were examined with a 
nucleator. 
The Duncan test was used for statistical 
comparisons between groups. Values of p less than 
0.05 were considered statistically significant. 
RESULTS AND DISCUSSION 
After 28 days of treatment, the body weights 
significantly decreased (p < 0.05) by about 19% and 
16% in the SRIH-14- and octreotide-treated 
animals, respectively. These results are in 
agreement with our previous findings obtained 
after an ICV administration of SRIH (Milošević et 
al., 1996). Other authors showed that SRIH reduces 
food intake both in man and in rat (Scalera and 
Tarozzi, 1998). 
The absolute weights of the adrenal glands 
significantly (p<0.05) decreased by 23% and 21% in 
the SRIH-14- and octreotide-treated groups, res-
pectively. The relative weights of the adrenal glands 
did not differ significantly between the SRIH-14- and 
octreotide-treated groups. The absolute volumes of 
adrenal glands significantly  (p<0.05) decreased by 
24% in the SRIH-14 and by 20% in octreotide-treated 
groups. These results are in agreement with our 
previous findings observed after ICV administration 
of SRIH (Milošević et al., 1996). 
Table 1. Effects of chronic treatment with SRIH-14 and 
octreotide treatments on body weight and adrenal weight in 
male rats 
Groups Body weight, (g) Absolute 
adrenal 
weight (mg) 
Absolute 
volumes of 
adrenal 
gland (mm3) 
controls 269.1 ± 22.9 18.1 ± 0.5 17.3 ± 0.5 
SRIH-14 217.2 ± 19.2a 
(-19%) 
13.7 ± 0.6a 
(-23%) 
13.2 ± 0.7a 
(-24%) 
octreotide 225.6 ± 12a 
(-16%) 
14.3 ± 1.2a 
(-21%) 
13.8 ± 1.1a 
(-20%) 
 
Figure 1. Effects of chronic SRIH-14 and octreotide treatments 
on the volume of chromaffin cells in male rats. The values are
the means ± SD, n=8, ap<0.05 in comparison with sham
operated 
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Compared to control rats, the relative volumes of 
the vascular tissue in the adrenal medulla decreased 
significantly (p<0.05) – by 40% and 25% in the 
SRIH-14 and octreotide-treated groups, respectively. 
Compared to the control rats, in the SRIH-14- and 
octreotide-treated groups the relative volumes of 
chromaffin and interstitial tissue increased insigni-
ficantly (p>0.05), by 6% and 5%, respectively. Aside 
from having numerous effects, SRIH possesses a 
vasoconstrictor activity (Patel, 1999). 
The cell volumes in chromaffin tissue which is 
made up of adrenaline- and noradrenalin-storing 
cells did not differ significantly between the SRIH-
14- and octreotide-treated groups, although a ten-
dency towards decrease was observed (Table 1). Sst 
mRNAs expression that was detected in the adrenal 
medulla suggests a possible role of SRIH in catecho-
lamine secretion (O'Carroll, 2003). 
The adrenal medullae in animals treated with either 
SRIH-14 or octreotide have changed stereological para-
meters. This information is of importance with regard 
to the clinical applications of somatostatin analogues. 
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